Metabolic Syndrome: Modification of the Fatty Acid Composition and Glucose-insulin Homeostasis

Denisenko, Yulia K.; Новгородцева, Т. П.; Zhukova, Natalia V.; Гвозденко, Т. А.; Аntonyuk, M. V.; Knyshova, V. V.; Nazarenko, A. V.

doi:10.9734/bjmmr/2015/18536

Cited by 4 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 48 articles examined by full-text, an additional 21 articles were excluded for various reasons (e.g., studies without providing n -3 PUFAs composition, studies from prospective cohort, or intervention studies). Finally, 27 studies were eligible for the present study, including 13 studies form Europe [ 8 , 9 , 13 , 14 , 15 , 17 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ], 10 studies from Asia [ 10 , 11 , 12 , 18 , 28 , 29 , 30 , 31 , 32 , 33 ], three studies from North America [ 16 , 34 , 35 ], and one study from South America [ 36 ] ( Table S1 ).…”

Section: Resultsmentioning

confidence: 99%

“…The difference of circulating n -3 PUFAs between cases and controls was also explored. No significant difference was found between cases and controls with respect to circulating ALA (WMD: 0.02; 95% CI: −0.02, 0.25) ( Figure S2 ) [ 9 , 11 , 12 , 13 , 15 , 16 , 17 , 21 , 27 , 28 , 31 , 33 , 36 ] and EPA (WMD: −0.02; 95% CI: −0.08, 0.03) ( Figure 4 ) [ 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 21 , 27 , 31 , 33 , 36 ], while circulating n -3 PUFAs (WMD: 0.24; 95% CI: 0.04, 0.43) ( Figure 4 ) [ 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 33 ], DPA (WMD: 0.07; 95% CI: 0.01, 0.14) ( Figure 5 ) [ 11 , 12 , 15 , 33 ] and DHA (WMD: 0.09; 95% CI: 0.01, 0.16) ( Figure 5 ) [ 9 , 10 , 11 ,…”

Section: Resultsmentioning

confidence: 99%

“…Two prospective cohort studies investigated the association of circulating fatty acids with MetS risk, and the results have suggested null [ 8 ] and inverse associations [ 9 ]. Meanwhile, Several cross-sectional and case-control studies have indicated that plasma/serum n -3 PUFAs was significantly higher in healthy subjects compared with patients with MetS [ 10 , 11 , 12 , 13 ], while some studies have suggested opposite and null associations [ 8 , 13 , 14 , 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis

Guo

Shi

et al. 2017

Nutrients

View full text Add to dashboard Cite

The associations between n-3 polyunsaturated fatty acids (PUFAs) and metabolic syndrome (MetS) risk have demonstrated inconsistent results. The present study aimed to investigate whether higher circulating n-3 PUFAs and dietary n-3 PUFAs intake have a protective effect on MetS risk. A systematic literature search in the PubMed, Scopus, and Chinese National Knowledge Infrastructure (CNKI) databases was conducted up to March 2017. Odd ratios (ORs) from case-control and cross-sectional studies were combined using a random-effects model for the highest versus lowest category. The differences of n-3 PUFAs between healthy subjects and patients with MetS were calculated as weighted mean difference (WMD) by using a random-effects model. Seven case-control and 20 cross-sectional studies were included. A higher plasma/serum n-3 PUFAs was associated with a lower MetS risk (Pooled OR = 0.63, 95% CI: 0.49, 0.81). The plasma/serum n-3 PUFAs in controls was significantly higher than cases (WMD: 0.24; 95% CI: 0.04, 0.43), especially docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). However, no significant association was found between dietary intake of n-3 PUFAs or fish and MetS risk. The present study provides substantial evidence of a higher circulating n-3 PUFAs associated with a lower MetS risk. The circulating n-3 PUFAs can be regarded as biomarkers indicating MetS risk, especially DPA and DHA.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis

Guo

Shi

et al. 2017

Nutrients

View full text Add to dashboard Cite

show abstract

“…Although the exact etiology of the MetS is not clearly understood, insulin resistance (IR) is considered as the principal factor for the pathogenesis of this syndrome [ 6 , 11 , 18 , 45 ]. As found by the insulin-modified, frequently sampled intravenous glucose tolerance assay, insulin sensitivity is significantly lower in patients with two or more components of the MetS compared to those with none of these components [ 2 ].…”

Section: Metabolic Syndrome: Definitions and Criteriamentioning

confidence: 99%

“…A decrease in the level of PUFAs has been established in patients with T2DM and diabetic retinopathy. It was found that the development of insulin resistance is preceded by a reduction of essential n-3 PUFAs in the cell membranes [ 6 ]. There are several reasons why n-3 PUFAs are important in the pathogenesis and prevention of MetS.…”

Section: Polyunsaturated Fatty Acids and Metabolic Syndrome Riskmentioning

confidence: 99%

Lipid-Induced Mechanisms of Metabolic Syndrome

et al. 2020

View full text Add to dashboard Cite

Metabolic syndrome (MetS) has a worldwide tendency to increase and depends on many components, which explains the complexity of diagnosis, approaches to the prevention, and treatment of this pathology. Insulin resistance (IR) is the crucial cause of the MetS pathogenesis, which develops against the background of abdominal obesity. In light of recent evidence, it has been shown that lipids, especially fatty acids (FAs), are important signaling molecules that regulate the signaling pathways of insulin and inflammatory mediators. On the one hand, the lack of n-3 polyunsaturated fatty acids (PUFAs) in the body leads to impaired molecular mechanisms of glucose transport, the formation of unresolved inflammation. On the other hand, excessive formation of free fatty acids (FFAs) underlies the development of oxidative stress and mitochondrial dysfunction in MetS. Understanding the molecular mechanisms of the participation of FAs and their metabolites in the pathogenesis of MetS will contribute to the development of new diagnostic methods and targeted therapy for this disease. The purpose of this review is to highlight recent advances in the study of the effect of fatty acids as modulators of insulin response and inflammatory process in the pathogenesis and treatment for MetS.

show abstract

Lipid Behavior in Metabolic Syndrome Pathophysiology

Marzoog

2022

CDR

View full text Add to dashboard Cite

: Undeniably, lipid plays an extremely important role in the homeostasis balance, since lipid contributes to the regulation of the metabolic processes. The metabolic syndrome pathogenesis is multi-pathway that composes neurohormonal disorders, endothelial cell dysfunction, metabolic disturbance, genetic predisposition, in addition to gut commensal microbiota. The heterogenicity of the possible mechanisms gives the metabolic syndrome its complexity and limitation of therapeutic accesses. The main pathological link that lipid contributes to the emergence of metabolic syndrome via central obesity and visceral obesity that consequently lead to oxidative stress and chronic inflammatory response promotion. Physiologically, a balance is kept between the adiponectin and adipokines level to maintain the lipid level in the organism. Clinically, extremely important to define the borders of the lipid level in which the pathogenesis of the metabolic syndrome is reversible, otherwise will be accompanied by irreversible complications and sequelae of the metabolic syndrome (cardiovascular, insulin resistance). The present paper is dedicated to providing novel insights into the role of lipid in the development of metabolic syndrome hence dyslipidemia is the initiator of insulin resistance syndrome (metabolic syndrome).

show abstract

Metabolic Syndrome: Modification of the Fatty Acid Composition and Glucose-insulin Homeostasis

Cited by 4 publications

References 16 publications

n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis

n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis

Lipid-Induced Mechanisms of Metabolic Syndrome

Lipid Behavior in Metabolic Syndrome Pathophysiology

Contact Info

Product

Resources

About